Company profile

Cabaletta Bio, Inc.

Pipeline1 asset

rese-celCABA-201 / CD19 / Autologous fully human 4-1BB CD19-CAR T cell therapy / Autoimmune disease
DermatomyositisRegistrationalrecruitingUSAntisynthetase syndromeRegistrationalrecruitingUSImmune-mediated necrotizing myopathyPhase 1/2recruitingUS

Latest news9 items

Jun 3, 2026

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Presentation / Abstract • Phase 1/2EULAR 2026 abstract release Wed, Jun 3, 2026, 7:00 AM EDT

May 14, 2026

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Presentation / Abstract • Phase 1/2EULAR oral presentation Thu, Jun 4, 2026, 9:15 AM BST

May 14, 2026

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Presentation / AbstractASGCT poster presentation Thu, May 14, 2026, 7:00 AM EDT

May 4, 2026

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Apr 28, 2026

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Presentation / Abstract

Apr 27, 2026

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Presentation / Abstract • Phase 1/2

Mar 23, 2026

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presentation / Abstract • Phase 1/2

Feb 24, 2026

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 5, 2026

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Cabaletta Bio, Inc. • Endpoint Arena